top of page
Search

How Long Does Patient Recruitment Take in the UK? Realistic Timelines by Study Type

Writer: Guy hudson
Guy hudson
6 days ago
9 min read

For most UK studies, patient recruitment takes weeks to many months, not a fixed number of days. A small, well-defined Phase I study may identify and enrol volunteers quickly, while a rare-disease or highly selective Phase III study can take considerably longer. The practical answer depends on the number of participants required, how many sites are active, the eligibility criteria, and whether potential participants can be identified through current clinical records.

This distinction matters because the UK's 150-day clinical trial target measures the journey from regulatory application to recruitment of the first participant for eligible commercial CTIMP studies. It does not mean that the full recruitment target will be completed in 150 days. This guide separates study set-up, first-patient-in, full-target recruitment and close-out so sponsors, CROs and research teams can build a more defensible timeline.

What Counts As The Recruitment Timeline?

A clinical trial recruitment timeline is the time required to move from an approved, recruitment-ready study to the number of participants needed for the protocol. It usually contains several distinct clocks:

  • Patient identification: locating people who may fit the broad disease and demographic profile.

  • Pre-screening and eligibility review: checking records and key criteria before an invitation is made.

  • Contact and informed consent: explaining the study, answering questions and documenting voluntary consent.

  • Screening and enrolment: completing protocol-defined assessments and formally enrolling eligible participants.

  • Retention and replacement: allowing for withdrawals, screen failures or dropouts that may require additional recruitment.

A useful planning document should therefore record at least three milestones: first patient in (FPI), the point at which the full recruitment target is reached, and recruitment close-out when screening and enrolment stop. Confusing these milestones is a common reason that a study appears to be "late" even when its first participant was recruited on time.

Realistic UK Timelines By Study Type

The ranges below are planning estimates, not regulatory standards or guarantees. They assume the study is approved, sites are genuinely ready, and recruitment activity begins with a workable referral or patient-identification process.

Study type

Typical recruitment profile

Indicative time to FPI

Indicative time to full target

Phase I

Often healthy volunteers or a narrow specialist group; usually concentrated at a small number of sites.

2–8 weeks

1–4 months

Phase II

Condition-specific criteria and safety assessments; moderate screening burden.

1–3 months

4–12 months

Phase III

Larger target, more sites and broader geography; operational consistency becomes critical.

2–6 months

9–24 months

Rare disease / highly selective

Small, dispersed population and complex confirmation of diagnosis or treatment history.

3–9+ months

12–36+ months

GP-led, data-enabled model

Potential participants are identified from current primary-care records before broad outreach, subject to approvals and GP capacity.

Initial cohorts in hours and days; FPI then depends on site readiness

Study-dependent; typically more predictable


The final column is the one sponsors should model most carefully. A study can reach FPI quickly and still miss its overall milestone if the remaining sites recruit slowly, screening failure is high, or the protocol creates a heavy visit burden. Conversely, a slower FPI may be acceptable if the selected sites have a credible flow of eligible participants and a strong monthly recruitment rate.

Why Phase And Protocol Design Change The Answer

Phase I Clinical Trial Recruitment

Phase I recruitment can be fast when the protocol needs healthy volunteers and the site has an established database, dedicated staff and a clear schedule. It can be slower for first-in-human studies involving complex safety criteria, specialist patients or intensive observation. The apparent speed of Phase I should not be used as a benchmark for later-stage studies.

Phase II Clinical Trial Recruitment

Phase II studies recruit people with the target condition and often require laboratory, imaging or prior-treatment criteria. The practical bottleneck is frequently not awareness; it is finding people who satisfy several criteria at the same time and can attend the required visits. Early feasibility should test the combined criteria, not just the prevalence of the condition.

Phase III Clinical Trial Recruitment

Phase III programmes typically need more participants and more sites. That creates a coordination problem: every site needs training, contracts, local capacity and a realistic patient funnel. A sponsor should forecast recruitment by site and month rather than applying one average rate across the whole country.

Rare Disease And Specialist Studies

Rare disease recruitment can take longer because the eligible population is small, geographically dispersed and sometimes difficult to confirm from routine coding alone. The best plan may use specialist centres, patient organisations, primary care and carefully governed record review together. A large static database is not the same as a reachable cohort, which is why volume and reach matter so much in rare disease trials.

The UK Set-Up Clock And The Recruitment Clock Are Different

The UK policy framework divides the 150-day set-up ambition into 60 days for combined regulatory review, 60 days from approval to study opening, and 30 days from opening to first participant. NIHR explains the three stages here.

The regulatory part of that clock has improved sharply. The government reported in April 2026 that the average set-up time for a commercial interventional trial had fallen from 169 days to 122 days, and later figures showed every approved study receiving combined review approval within 60 days in August and September 2026. The later stages are where the pressure remains. The latest UK Clinical Research Delivery KPIs show 67% of studies recruiting a first participant within 30 days of opening, against a 90% target.

The ABPI's annual clinical trials report, published in November 2026, tells the same story from an industry perspective. Just 17,618 people took part in industry clinical trials in the NHS in 2025/26, 31% fewer than in 2022/23. On average, 35% of studies opened to recruitment within 60 days of approval, and 53% recruited their first patient within 30 days of opening. These figures use different scopes and reporting windows, so they should not be merged into one universal average.

The planning lesson is straightforward: regulatory approval has become faster, but that has not solved patient identification. Recruitment readiness needs its own owner, metrics and contingency plan.

What Usually Delays Patient Recruitment?

  • Feasibility based on historic or unverified counts rather than current patient availability.

  • Eligibility criteria that are clinically necessary but operationally difficult to verify before screening.

  • Sites selected for reputation or geography without a quantified patient funnel.

  • Slow contracts, training, pharmacy preparation or local approvals after central approval.

  • Low response rates because the first approach is unclear, poorly timed or disconnected from trusted care.

  • High screen-failure or dropout rates, which quietly increase the number of people who must be approached.

  • Fragmented or out-of-date data that prevents teams from seeing where eligible patients are concentrated.

Many of these problems are fixed before a patient is ever contacted. As our article on the hidden cost of slow recruitment explains, validating feasibility, geography and patient availability early is far more effective than trying to recover lost time with extra advertising later.

How To Translate Recruitment Rates Into Calendar Time

A timeline becomes more useful when it shows the maths behind the estimate. Suppose a study needs 120 enrolled participants, expects a 30% screening-to-enrolment conversion rate, and has six active sites. The sites would need to screen about 400 people in total. If each site can screen 12 suitable candidates per month, the theoretical recruitment period is about six months, before allowing for staggered site activation, holidays, uneven demand or replacement of dropouts.

That simple calculation is only a starting point. Recruitment rarely behaves like a straight line. Early months may be slower while sites train and refine the referral pathway. A promising site may then accelerate, while another may produce many screen failures. For this reason, forecasts should include a conservative case, a base case and an upside case, each with explicit assumptions.

The most useful dashboard combines leading and lagging indicators: time from site readiness to first approach, number of records reviewed, number of people contacted, response rate, screening appointments, screen-failure reasons, consent rate and enrolment per site per month. These measures show where the funnel is narrowing. They also help a sponsor decide whether the remedy is more patient identification, clearer communication, additional screening capacity or a protocol discussion.

How To Build A More Defensible Recruitment Forecast

1. Start With The Required Participant Funnel

Work backwards from the target. If 100 participants are needed and the expected screening-to-enrolment conversion is 25%, the team needs about 400 screened candidates. If only half of approached candidates respond, the required contact pool is larger again. Treat these as assumptions to test, not facts to decorate a spreadsheet.

2. Validate The Hardest Criteria First

Do not begin with the easiest inclusion criterion. Test the combination most likely to shrink the pool: biomarker, treatment history, disease severity, age range, geography or timing. Ask each proposed site how the criterion will be verified and how quickly the relevant record can be reviewed.

3. Model Sites Separately

A country-level average hides underperformance. Create a site-level forecast with expected eligible patients, monthly contact capacity, screening capacity, expected conversion and a start date. Set trigger points for adding a site or changing the recruitment approach before the target is already at risk.

4. Protect Consent And Data Governance

Speed cannot replace informed consent or lawful handling of health information. The HRA's clinical-trial regulations guidance confirms that the updated UK regulations, in force since 28 April 2026, are designed to reduce unnecessary burden while protecting participants, and that informed consent must remain informed, freely given and explicit.

Can GP-Led Patient Identification Reduce The Timeline?

Yes, particularly at the front of the process, where most of the uncertainty sits. When a GP practice reviews its own current records against confirmed study criteria, the research team starts with a targeted cohort rather than waiting for responses to broad outreach. GP-led identification does not remove regulatory review, site activation, screening or consent, but it replaces guesswork with real patient numbers from the very start.

This is the model TrialChoices was built on. As one of the largest patient recruitment firms in Europe, TrialChoices works directly with GP practices that collectively care for 5 million UK patients, with a further 9 million reachable through wider Primary Care Network (PCN) searches on a pre-planned basis. Because the records are live and stay within the NHS, initial cohorts can be identified in hours and days rather than weeks and months. In one live study, 42 rare disease patients were identified in just four hours.

The GP process is simple. TrialChoices presents the opportunity to its GP partners, each practice opts in or out, and once selection criteria and logistics are confirmed the practice team reviews its own patient data and connects suitable people with the research team. Most UK clinical research starts and ends with the GP, so going direct removes unnecessary layers between the protocol and the patient. You can read more on our researchers page.

Before you lock a timeline, it is worth agreeing a few things with your recruitment partner: how many practices can review the criteria, who makes the first contact, how quickly you will receive a cohort estimate, how screen failures will be tracked, and what happens if the first pool is smaller than expected. Clear answers to these questions make your forecast far easier to defend.

A Practical Timeline Checklist For Sponsors And CROs

  1. Define FPI, full-target recruitment and close-out as separate milestones.

  2. Document the participant funnel from potential record match to consented enrolment.

  3. Separate regulatory, site-readiness and patient-recruitment assumptions.

  4. Use current, governed patient information where possible, and record its date and scope.

  5. Forecast monthly recruitment by site, not only as a national total.

  6. Agree intervention triggers before performance falls materially behind plan.

  7. Review diversity, participant burden and retention alongside speed.

Frequently Asked Questions

How long does it take to recruit patients for a clinical trial in the UK?

A realistic range is several weeks to several years. Phase I studies with healthy volunteers may fill in one to four months, while Phase III, rare-disease and highly selective studies commonly require many months or longer. The target, sites, criteria and patient-identification method matter more than the phase label alone.

Does the UK 150-day target mean a trial is fully recruited in five months?

No. It is an end-to-end set-up measure that ends when the first participant is recruited for eligible studies. Full-target recruitment may continue for months or years afterwards.

What is the fastest way to improve a recruitment forecast?

Validate the hardest eligibility criteria against current patient availability before finalising sites and launch plans. Then model conversion, screening capacity and monthly recruitment by site.

Can real-time patient data speed up recruitment?

It can make a significant difference to the start of recruitment, because teams see real patient numbers rather than estimates and can identify initial cohorts in hours and days. Eligibility, consent and site capacity still need to be managed, but starting with an accurate cohort removes one of the biggest sources of delay.

Plan The Timeline Before The Delay

The most useful recruitment timeline is not a single optimistic number. It is a transparent model that shows what must happen between approval, patient identification, screening, consent and enrolment, with clear assumptions and fallback actions. UK performance data shows that approval and set-up reforms can move quickly while recruitment still lags. Sponsors that test patient availability early are better placed to choose sites, set realistic targets and act before a shortfall becomes a programme delay.

Contact TrialChoices

If you are planning a UK study and want to test recruitment feasibility against real primary-care populations, TrialChoices can help. Share your protocol synopsis, key eligibility criteria and target geography, and we can show you what an initial cohort could look like.

Call +44 (0)7711 248 610 or email info@trialchoices.org to find out how direct access to millions of UK patients can shorten your recruitment timeline.


 
 
 

Recent Posts

See All

Comments


bottom of page